Skip to main content
Log in or Sign up
to access My Account functionalities
Find similar products:
-
By ATC code
My Account Area
Find similar products:
-
By ATC code
Report side effect
Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to
site
Back to top
Ashton and Parsons Teething Powders
Active Ingredient:
Company:
Alliance Pharmaceuticals
See contact details
About Medicine
General Sales List
My Account Area
This information is for use by healthcare professionals
Last updated on emc: 17 Aug 2022
Quick Links
1. Name of the medicinal product
Ashton and Parsons Teething Powders
2. Qualitative and quantitative composition
Each sachet contains powder impregnated with 0.002ml of tincture from Matricaria (Matricaria recutita L.) flower (1:4-5). Extraction solvent: Ethanol 70% v/v
Each sachet contains 130mg lactose
For the full list of excipients, see section 6.1
3. Pharmaceutical form
Oral powder.
Fine, white, crystalline powder.
4. Clinical particulars
4.1 Therapeutic indications
A traditional herbal medicinal product used for the symptomatic relief of teething pain and the symptoms associated with teething which are sore and tender gums, flushed cheeks and dribbling based on traditional use only.
4.2 Posology and method of administration
For oral short term use only.
Method of administration: Oral use whilst the infant is held in a sitting or upright position. Put the powder slowly on the front of the infant's tongue, a little at a time, allowing the powder to fully dissolve.
This product is only intended for use in teething infants.
This product is not recommended for use in infants under 3 months old.
| Age | Dose recommendations | Additional dosing |
| Infants aged 3-6 months | Use a teaspoon to give the powder. Half the contents of one sachet in the morning and the other half in the evening. The sachet should be divided in half by emptying half the contents onto the teaspoon and retaining the other half in the sachet | If the infant is very restless, the dose may be repeated every 1, 2 or 3 hours if necessary until improvement occurs. The maximum dose is 6 doses in 24 hours. |
| Infants over 6 months | One sachet in the morning and 1 sachet in the evening |
If symptoms worsen or persist after 7 days of using this product, a doctor or qualified healthcare practitioner should be consulted.
4.3 Contraindications
Hypersensitivity to the active substance, any members of the Asteraceae/ Compositae family or to any of the excipients.
4.4 Special warnings and precautions for use
Matricaria may precipitate an allergic reaction or exacerbate existing symptoms in susceptible individuals (e.g. asthmatics).
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Fertility, pregnancy and lactation
The use of this product in pregnancy and lactation is not applicable.
Studies on the effects on fertility have not been performed.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Hypersensitivity reactions including urticaria, contact sensitivity, rash; application site reactions including lesions (tongue).
The frequency is not known.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
4.9 Overdose
Overdosage with this product would cause diarrhoea due to excessive lactose intake.
Treatment would be by withdrawal of the product and supportive measures such as oral rehydration therapy.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.2 Pharmacokinetic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.3 Preclinical safety data
Tests on reproductive toxicity and carcinogenicity have not been performed.
Reverse mutation assays (Ames test) on bacteria indicated that the product was not mutagenic in Salmonella typhimurium (strains TA 98, TA 100, TA 1535, TA 1537 and E.Coli strain WP2 uvrA) mutation assay with or without metabolic activation.
6. Pharmaceutical particulars
6.1 List of excipients
Lactose.
6.2 Incompatibilities
None stated.
6.3 Shelf life
36 months unopened.
6.4 Special precautions for storage
Store below 25° C
6.5 Nature and contents of container
The powder is contained in a paper/PE/Al foil/PE laminate sachet. 10, 20 or 30 sachets are packed in a boxboard carton.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
No special requirements.
7. Marketing authorisation holder
Alliance Pharmaceuticals Limited
Avonbridge House
Bath Road
Chippenham
Wiltshire
SN15 2BB
UK
8. Marketing authorisation number(s)
THR 16853/0076
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation 08/11/2012
Date of renewal 17/02/2022
10. Date of revision of the text
17/02/2022
Alliance Pharmaceuticals
Address
Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone
+44 (0)1249 466 966
Fax
+44 (0)1249 466 977
Medical Information e-mail
[email protected]
Delivered to you by
